No Data
No Data
Earnings Preview: SRPT to Report Financial Results Post-market on November 06
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Business And Shares Still Trailing The Industry
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Baird Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
No Data
No Data